Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Corton Capital Inc.

Corton Capital Inc. raised its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 25.6% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 21,741 shares of the company’s stock after purchasing an additional 4,433 shares during the quarter. Corton Capital Inc.’s holdings in Olema Pharmaceuticals were worth $82,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its stake in Olema Pharmaceuticals by 22.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 14,892 shares of the company’s stock valued at $56,000 after buying an additional 2,743 shares in the last quarter. Boothbay Fund Management LLC raised its stake in Olema Pharmaceuticals by 10.8% during the fourth quarter. Boothbay Fund Management LLC now owns 31,226 shares of the company’s stock valued at $182,000 after buying an additional 3,056 shares in the last quarter. Virtus ETF Advisers LLC raised its stake in Olema Pharmaceuticals by 43.1% during the fourth quarter. Virtus ETF Advisers LLC now owns 10,579 shares of the company’s stock valued at $62,000 after buying an additional 3,185 shares in the last quarter. ProShare Advisors LLC raised its stake in Olema Pharmaceuticals by 30.2% during the fourth quarter. ProShare Advisors LLC now owns 14,226 shares of the company’s stock valued at $83,000 after buying an additional 3,298 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Olema Pharmaceuticals by 2.6% during the first quarter. Bank of New York Mellon Corp now owns 131,994 shares of the company’s stock valued at $496,000 after buying an additional 3,328 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on OLMA. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Olema Pharmaceuticals in a research note on Monday, April 28th. Oppenheimer lowered their target price on Olema Pharmaceuticals from $25.00 to $22.00 and set an “outperform” rating for the company in a report on Wednesday, May 14th. Finally, The Goldman Sachs Group lowered their target price on Olema Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, May 14th.

Olema Pharmaceuticals Trading Up 3.1%

NASDAQ:OLMA opened at $4.71 on Monday. The firm has a market capitalization of $322.26 million, a PE ratio of -2.34 and a beta of 1.90. The stock has a 50 day moving average of $4.56 and a 200-day moving average of $4.67. Olema Pharmaceuticals, Inc. has a 52 week low of $2.86 and a 52 week high of $16.62.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its earnings results on Tuesday, May 13th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.13. As a group, analysts predict that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current fiscal year.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.